A new test could help patients with advanced bowel cancer get the best treatment for their disease, according to a clinical trial published in JAMA Oncology.
The trial studied almost 1,200 patients at hospitals all over the UK with advanced bowel cancer whose first chemotherapy treatment had stopped working and who were starting a second chemotherapy treatment called irinotecan.
In the trial, each patient had their cancer tested for a gene called RAS. If there were no faults in the gene, they went on to receive irinotecan either alone or together with a new targeted cancer drug called panitumumab. The research showed that some patients benefited from adding the new drug but others did not and further studies were carried out to find out why.
Tumour samples from 323 of the trial patients were tested for levels of two proteins - called AREG and EREG - which are produced by some cancer cells to help them grow. Panitumumab blocks these proteins, stopping tumours developing.
The team showed that for patients with high levels of the proteins, the drug combination stopped cancer growth for nearly twice as long as irinotecan alone - an average of eight months compared with four and a half months. But the drug did not work for patients with low levels of the proteins.
Study author Dr Jenny Seligmann, said: "These results are very promising. Our task now is to develop a fast and reliable test for the two proteins that can be offered to patients before they start treatment, to help select the right drugs to use."
"Thanks to research we now have new cancer drugs that work in very specific ways, targeting individual rogue molecules in cancer cells. These drugs can be of enormous help to some patients, but not others - so as well as developing new treatments it is vital that we find the right way to select the best treatment for each individual patient. This will help patients to have more time with their loved ones, and to avoid the distress of going through ineffective treatment."